Pacific Biosciences of California, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark Van Oene
- Full Time Employees
- 485
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1305 O’Brien Drive Menlo Park CA United States of America 94025
- IPO Date
- Oct 27, 2010
- CIK
- 0001299130
- Website
- pacb.com
- Similar Companies
- Business
- Pacific Biosciences of California, Inc. (PacBio) designs, develops, and manufactures advanced sequencing solutions to resolve genetically complex problems in life sciences research and clinical applications; its core offerings include long-read HiFi sequencing systems such as the Revio production-scale platform delivering up to 120 Gb per SMRT Cell with SPRQ-Nx chemistry, the Vega benchtop system providing 60 Gb per SMRT Cell, and legacy Sequel II and Sequel IIe instruments; short-read sequencing via the Onso system powered by sequencing by binding (SBB) chemistry achieving 90% Q40 accuracy; consumables encompassing SMRTbell library preparation kits, reagent kits including ligase, buffers, exonucleases, flow cells, clustering, and sequencing reagents; and software solutions like SMRT Link for analysis, Paraphase variant caller, and applications for whole genome sequencing, targeted sequencing, epigenetics, RNA isoform sequencing, and PureTarget assays for repeat expansions and carrier screening. The company serves academic and governmental research institutions, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical firms, and agricultural companies across the Americas, Europe, Middle East, Africa, Asia Pacific including China and Japan, and other regions through direct sales and distribution partners. Incorporated in 2000 and headquartered at 1305 O'Brien Drive in Menlo Park, California, PacBio operates in the biotechnology sector focusing on human genetics, plant and animal sciences, infectious disease, oncology, and emerging multiomic applications. Recent developments include the launch of SPRQ-Nx chemistry in 2025 targeting up to 40% reduction in HiFi genome sequencing costs to under $300 per genome at scale with beta testing on Revio starting November 2025 and commercial availability in 2026; expanded PureTarget portfolio with updated repeat expansion and new carrier screening panels plus 96-plex automation kits; distribution agreement with Haorui Gene in 2025 to promote platforms including Vega in China's clinical labs for blood typing genomics and precision medicine; Class III medical device approval in China for Sequel II CNDx system via partner Berry Genomics in November 2025; partnership with Epicycle for FiberSeq chromatin analysis integration; selection of Revio for the U.S. National Institute on Aging's Long Life Family Study sequencing up to 7,800 genomes and epigenomes, and the Korean Pangenome Reference Project for over 1,000 genomes; and publication of HiFi Solves EMEA Consortium preprint demonstrating 100% detection of pathogenic variants in complex regions.
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
Pacific Biosciences: It's Only Getting Worse
Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript
Pacific Biosciences of California Q2 Earnings Call Highlights
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
PacBio Announces Second Quarter 2026 Financial Results
PacBio Announces Second Quarter 2026 Financial Results
PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
What's in Store for These 4 Healthcare Companies This Earnings Season?
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $1.83 Consensus PT from Brokerages
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Amova Asset Management Americas Inc. Has $9.22 Million Stock Position in Pacific Biosciences of California, Inc. $PACB
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Here's Why You Should Add PacBio Stock to Your Portfolio Now